2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 260-262
Clinical issues with T cell engagers (scheduling, out-patient delivery, CRS prophylaxis, tumor flare, maintenance). One abstarct on bone modifying therapy in myeloma that didn't fit elsewhere.
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

970 Prophylactic tocilizumab prior to bispecific antibody step-up dosing for relapsed/refractory multiple myeloma

Mikhaila Rice, PharmD, Jonathan Kissam, PharmD2, Ariel Grajales-Cruz, MD3, Jing Christine Ye, M.D., MSc4, Andrew Jay Portuguese, MD5, Poy Theprungsirikul, MD6, Masooma Shifa Rana, MBBS7, Andre Corraes8, Samer Al Hadidi, MD9, James A Davis, PharmD, BCOP10, Kelley Julian, PharmD, BCOP11, Francesca Cottini, MD12, Timothy Obrien13, Murali Janakiram, MBBS14, Darren Pan, MD15, Christopher J. Ferreri, MD16, Binoy Yohannan, MD17, Noa Biran, MD18, Chenyu Lin, MD19, Ana Maria Avila Rodriguez, MD20, Alissa Visram, MD, MPH21, Megan M Herr, PhD22, Nisha Joseph, MD23, Doris K. Hansen, MD24, Kenneth H. Shain, MD, PhD25, Melissa Alsina, MD26, Megan Vince, PharmD, BCOP27, Lana Alhashimi, PharmD28, Wei Wei, MS29, Mousa Thalji, MD30, Mackenzie Maberry, MD31, Tiffany Richards, PhD, NP32, Krina Patel Jr, MD, MSc33, Danai Dima, MD34, Rahul Banerjee, MD35, Shonali Midha, MD36, Omar Nadeem, MD37, Surbhi Sidana, MD38, Lekha Mikkilineni, MD, MA39, Malvika Gupta, MD40, Yi Lin Jr, MD, PhD41, Allison Tanner, PA42, Larry D Anderson Jr, MD, PhD43, Anthony Dominick44, Ashley Rosko, MD45, Daniel Schrum46, Doug W. Sborov, MD, MS47, Jack Khouri, MD48, Omar Puglianini, MD49
1 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
2 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 MD Anderson, Houston, Texas, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Stanford University, Stanford, California, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 UT Southwestern Medical Center, Dallas, Texas, United States
10 MUSC Health Hematology Oncology at Hollings Cancer Center, Charleston, South Carolina, United States
11 Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 Ohio State University, Columbus, Ohio, United States
13 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
14 City of Hope, Duarte, California, United States
15 University of California San Francisco, San Francisco, California, United States
16 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
17 University of Minnesota, Minneapolis, Minnesota, United States
18 Hackensack Meridian, Hackensack, New Jersey, United States
19 Duke University, Durham, North Carolina, United States
20 University of Illinois Chicago, Chicago, Illinois, United States
21 McMaster University, Hamilton, Ontario, Canada
22 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
23 Emory Winship Cancer Institute, Atlanta, Georgia, United States
24 Moffitt Cancer Center, Tampa, Florida, United States
25 Moffitt Cancer Center, Tampa, Florida, United States
26 Moffitt Cancer Center, Tampa, Florida, United States
27 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
28 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
29 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
30 MD Anderson, Houston, Texas, United States
31 MD Anderson, Houston, Texas, United States
32 MD Anderson, Houston, Texas, United States
33 MD Anderson, Houston, Texas, United States
34 Fred Hutch Cancer Center, Seattle, Washington, United States
35 Fred Hutch Cancer Center, Seattle, Washington, United States
36 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
37 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
38 Stanford University, Stanford, California, United States
39 Stanford University, Stanford, California, United States
40 Mayo Clinic, Rochester, Minnesota, United States
41 Mayo Clinic, Rochester, Minnesota, United States
42 Mayo Clinic, Rochester, Minnesota, United States
43 UT Southwestern Medical Center, Dallas, Texas, United States
44 MUSC Health Hematology Oncology at Hollings Cancer Center, Charleston, South Carolina, United States
45 Ohio State University, Columbus, Ohio, United States
46 Duke University, Durham, North Carolina, United States
47 Huntsman Cancer Institute, Salt Lake City, Utah, United States
48 Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
49 Moffitt Cancer Center, Tampa, Florida, United States

Introduction: Bispecific antibodies (BsAb) have demonstrated efficacy in patients with relapsed and refractory multiple myeloma (RRMM); however, these agents confer a significant risk for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) during the step-up dosing period. Rates of all grade CRS range from 40-80% with approved BsAb, requiring intensive monitoring and prompt management with steroids or tocilizumab. The high risk for CRS during step-up dosing is frequently a barrier to outpatient and local BsAb initiation. Prophylactic tocilizumab (toci ppx) prior to BsAb initiation has been shown to decrease CRS rates in several single institution studies. Here we report findings from a large, multicenter cohort.

Methods: This multicenter, retrospective study included patients who initiated elranatamab (elra), linvoseltamab (linvo), talquetamab (talq), or teclistamab (tec) at 21 academic institutions prior to September 30th, 2025. In patients receiving toci ppx, this was provided as a single dose prior to initiation of bispecific therapy step-up dosing per institutional protocols. Outcomes included incidence and severity of CRS and ICANS, incidence of infection, progression free survival (PFS), and overall survival (OS). Severity of CRS and ICANS was evaluated using ASTCT Consensus Grading. Chi-square test and Wilcoxon rank sum test were used for comparisons between toci ppx and no toci ppx groups. Kaplan-Meier method and log rank test were used for PFS and OS estimates and comparisons.

Results: Of 2026 patients included, median age was 68 years (range 30-95) and 50.9% were male. Most patients had an ECOG of 0-2 (91.6%). Patients received a median of five prior lines of therapy (range 1-20). Toci ppx was provided to 241 (11.9%) patients, including 43/246 (17.5%) initiating elra, 18/20 (90.0%) initiating linvo, 114/804 (14.2%) initiating talq, and 66/956 (6.9%) initiating tec. Exposure to prior BCMA-directed therapy was higher in the toci ppx group (53.7% vs 45.0%, p=0.011). Extramedullary disease was noted in 20.9% of patients in toci ppx group vs 22.8% in the no toci ppx group (p=0.515). Plasma cell leukemia was noted in 12.6% of patients in toci ppx group vs 7.8% in the no toci ppx group (p=0.014). Pre-treatment marrow burden of >50% plasma cells was noted in 31.8% of patients in toci ppx group vs 31.4% in the no toci ppx group (p=0.927). Baseline lactate dehydrogenase, beta-2 macroglobulin, and ferritin were not statistically different between groups. Baseline CRP was higher in the no toci ppx group (median 3 mg/dL (IQR 0.63-9) vs 1 mg/dL (IQR 0.3-5.1), p<0.0001). CRS occurred in 76 (31.5%) patients who received toci ppx compared to 959 (53.7%) patients who did not receive it (p <0.0001). With toci ppx, CRS incidence decreased from 48.8% to 25.6% for elra, from 59.9% to 38.6% for talq, and from 50.2% to 30.3% for tec. Of the 20 patients who received linvo, one experienced CRS, and this patient received toci ppx. A decrease was seen in grade 1 CRS (19.5% with toci ppx vs 38.4% without) and grade 2 CRS (8.7% with toci ppx vs 13.4% without), but rates of grade 3 or higher CRS were similar (3.3% with toci ppx vs 2% without). ICANS occurred in 30 (12.4%) patients who received toci ppx compared to 240 (13.5%) patients who did not receive it (p=0.661). Infection occurred in 80 (33.3%) patients who received toci ppx compared to 847 (47.7%) patients who did not receive it (p<0.0001). In the toci ppx group vs no toci ppx group, 23.8% vs 31.3% achieved a CR or better, 16.7% vs 19.7% achieved a VGPR, and 24.2% vs 13.5% achieved a PR, respectively. Median follow-up was 15.7 months (range 0.2-51.6 months). Median PFS was 9.4 months (95% CI 7.8 – 12.9) in the group that received toci ppx and 9.4 months (95% CI 8.3 – 10.8) in the no toci ppx group (p=0.81). Median OS was 22.8 months (95% CI 16.7 – not reached) in the group that received toci ppx and 24.9 months (95% CI 22.6 – 27.4) in the no toci ppx group (p=0.88).

Conclusions: CRS incidence was significantly lower in patients who received toci ppx with similar survival outcomes, though severe (grade ≥3) CRS rates were not meaningfully reduced. Rate of ICANS was not different between groups. Infection rates were lower in the toci ppx group. This investigation confirms prior findings, demonstrating benefit of toci ppx prior to BsAb initiation. Toci ppx may facilitate safe outpatient administration of BsAb and increase patient access.

Mikhaila Rice, PharmD: No relevant conflicts of interest to declare.